Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IMIPRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,153 records · Page 64Linked to original sources
PubMed1990

Imipramine pharmacokinetics in depressed geriatric patients.

Pharmacokinetics of single dose (25 mg i.m.) of imipramine was studied in geriatric and young adult patients with mood disorders requiring antidepressant treatment. Imipramine and its principal metabolites were determined by means of a high performance liquid chromatography method with electrochemical detection. Serum concentrations analysis was performed according to a bicompartmental open model. A relationship between age and kinetic parameters such as area under the curve, elimination phase constant, half-life and total body clearance was observed. Significant differences were demonstrated between elderly and young adult patients when comparing these parameters. It is concluded that geriatric patients treated with imipramine should receive doses of about 60% of those of young adults.

Adult↗
PubMed1975

[Changes in imipramine induced noradrenaline potentiation by varying activity of gastric juice under oral medication].

From the serial studies on imipramine dependent noradrenaline (NA) rise at different values of gastric acid with 336 registrations of blood pressure, it follows that a lawful relation exists between imipramine absorption and gastric juice acidity. At pH values of 3.5--6.0 a distinct decreased absorption of orally supplied imipramine was stated. After changing the pH value by acid substitution, a full absorption is reached. This state seems to be of special practical importance in the treatment of depression with thymoleptics.

Achlorhydria↗
PubMed1989

Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation.

Prior studies suggest that the addition of lithium salts may enhance treatment responses in depressions that have not responded to tricyclic antidepressants. The authors report on the efficacy of lithium augmentation in an open-label study of 20 outpatients with recurrent major depression who had not responded to greater than or equal to 12 weeks of treatment with imipramine (mean dosage = 256 mg/day) and psychotherapy. Only 1 patient (5%) responded during the first week of treatment, but the cumulative response rate increased to 65% during the 6-week clinical trial. Improvement in patients receiving lithium augmentation was significantly greater than the improvement observed in a historical control group of imipramine-resistant patients who received continued treatment with the imipramine-psychotherapy combination. The results support the usefulness of a 6-week trial of lithium augmentation in outpatients with resistant depression. It remains unclear whether the effectiveness of lithium augmentation is due to a true potentiation effect, a primary antidepressant effect by lithium, or a combination of both those factors.

Adult↗
PubMedDate not supplied

Interaction between central effects of ethanol and tricyclic antidepressants, imipramine and amitriptyline in mice and rats.

The effect of a combined treatment with ethanol and imipramine or amitriptyline was tested in mice and rats. The antidepressants were given in one or, in some experiments, in 21 daily doses of 10 mg/kg each. In mice the effect of antidepressants was tested on acute toxicity, disturbances of rota-rod performance, hypothermia and sleeping induced by ethanol, in rats the effect of the antidepressants on the development of tolerance to sleep-inducing and hypothermic action of ethanol was investigated. Amitriptyline showed a tendency to pontentiate the ethanol-induced acute toxicity, while imipramine did not change it. Given in a single dose the antidepressants have a tendency to potentiate the impairment of motor coordination induced by ethanol, but after a prolonged administration did not influence the ethanol effect in the rota-rod test. The antidepressants enhance ethanol-induced hypothermia and prolong the ethanol sleeping time. The development of tolerance to hypnotic effect of ethanol in rats is not affected by amitriptyline and imipramine, but the antidepressants prevent the development of tolerance to hypothermic effect.

Amitriptyline↗
PubMed1989

[Thrombocyte binding sites for 3H-imipramine in patients with depression].

The purpose of the work was to test the validity of parameters of binding sites for 3H-imipramine as a biological marker of endogenous depression. Using the standard WHO method, the author assessed parameters of the specific binding of 3H-imipramine on platelet membranes in 23 controls and in 13 depressive patients. At the same time she assessed parameters of the high-affinity component of the specific bond which depends on the presence of sodium ions in the medium. On comparison of the binding characteristics of platelets in depressive patients, diagnosed according to several diagnostic and classification systems (ICD-9, RDC, DSM-III) and controls, the author did not reveal any statistically significant differences in parameters of the specific binding nor in parameters of the binding depending on Na+ ions. The author discusses possible causes of the revealed inter- and intraindividual variability of parameters of the imipramine binding on platelet membranes in humans.

Adult↗
PubMed1989

Adequate treatment with imipramine in continuation treatment.

Maintenance treatment studies done with tricyclic antidepressants have used the equivalent of 150 mg or less of imipramine in prophylactic clinical trials. In an ongoing 3-year maintenance trial, the authors are using imipramine in dosages greater than 150 mg/day for both acute and continuation treatment (4 to 6 months) of recurrent depression in order to test the efficacy of this dosage level. Fifty-seven depressed patients who received tricyclic drug treatment and interpersonal psychotherapy during the acute and continuation phases of the study tolerated this dosage level well (mean dose, 217 mg/day of imipramine), reported few adverse effects on a somatic symptom checklist, and demonstrated a high level of compliance as shown by plasma concentration/dosage (L/D) ratios. The authors found that the time course of the L/D ratio is associated with higher steady-state plasma concentrations than those observed with similar dosages in shorter-term tricyclic antidepressant treatment.

Adult↗
PubMed1989

Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).

Seventy five patients, diagnosed according to the Structured Clinical Interview for DMS III ("unipolar", Major depression, single or recurrent, with or without melancholia) were treated, in a double-blind fashion, with either moclobemide, imipramine or placebo, during six weeks. The three treatment groups were homogeneous as far as demographic and clinical characteristics were concerned. Patients were in their forties, predominantly females and with long lasting (more than six months) episodes of moderate or severe depressions. From day seven onwards most patients took moclobemide 600 mg/d, imipramine 200 mg/d or 6 caps/d of placebo; only two cases took lower dosages due to intolerance. There were eleven drop-outs, evenly scattered among the three groups. Outcome assessed by means of the Hamilton Scale for Depression and Global Efficacy Evaluations showed a very significant superiority of the two active drugs over placebo. The efficacy of the two drugs was comparable. Side effects were significantly more frequent and more severe in the imipramine group. The tolerability of moclobemide was similar to placebo. These findings are discussed in relation to methodological issues. They point to the conclusion, that moclobemide may be the true "second generation antidepressant", comparably efficacious to the traditional compounds, producing far less side-effects, and because it is reversible, not requiring dietary or drug restrictions in clinical practice.

Adult↗
PubMed1985

[Isolation of substances inhibiting the specific binding of imipramine and serotonin uptake from the brain of the bull].

Several fractions that inhibit specific binding of 3H-imipramine and reverse uptake of 3H-serotonin in rat brain synaptosomes were obtained by gel chromatography on Sephadex G-10 from an acidic extract of brain homogenates. The profiles of inhibition of 3H-imipramine specific binding and reverse uptake of 3H-serotonin were found to be in a good agreement. This finding suggests that substances identified in the brain extract may have both types of activities. Further investigations relative to the purification and identification of the substances isolated from bovine brain should be aimed at the search for endogenous ligands for the "imipramine receptor".

Animals↗
PubMed1985

Characterization of endogenous inhibitors of [3H]-imipramine binding and [3H]-serotonin uptake from rat serum.

The effects of rat serum extracts on the uptake of [3H]-serotonin and the displacement of [3H]-imipramine binding in rat forebrain synaptosomes and human platelets was studied. Deproteinated rat serum markedly inhibited synaptosomal [3H]-serotonin uptake in a dose-dependent and reversible manner. The crude extract was fractionated by C18-reverse phase HPLC. Three major peaks of inhibitory activity were found. One of the peaks was identified as serotonin and was significantly reduced after chronic reserpinization. The second major peak inhibited both [3H]-serotonin uptake and [3H]-imipramine binding in synaptosomes and platelets. This fraction had a minimal effect on the uptake of [3H]-norepinephrine, [3H]-dopamine or [3H]-GABA and was less effective in inhibiting [3H]-desipramine binding than [3H]-imipramine binding.

Animals↗
PubMed1988

Continuation and maintenance treatment trials of adjunctive imipramine therapy in patients with postpsychotic depression.

Four of five patients who had had an operationally defined syndrome of postpsychotic depression, which had been responsive to adjunctive imipramine added to an ongoing regimen of fluphenazine decanoate and benztropine, suffered a return of depressive symptomatology following the tapering of the adjunctive imipramine 6 months after the initial response to imipramine therapy. Four comparison patients who were not tapered experienced no such reexacerbations (p = .04). The authors discuss implications of this finding for maintenance adjunctive antidepressant treatment strategies.

Benztropine↗
PubMed1988

Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.

Plasma levels of imipramine and desipramine were monitored in a series of 13 patients with postpsychotic depressions who had a fixed dose of imipramine (150 mg/day) added to their clinically adjusted, stable dose of fluphenazine decanoate. Despite the potential for metabolic inhibition of the tricyclic drug by the neuroleptic drug, no relationship was found between the fluphenazine dose and the subsequent plasma concentrations of imipramine and desipramine. However, plasma antidepressant levels after 1 week at a low dose (50 mg/day) identified patients who later generated high plasma antidepressant levels at the full antidepressant dosage. The clinical implications of these observations are discussed.

Adult↗
PubMed1987

The effect of imipramine on predatory behavior and locomotor activity in cats.

The behavior toward mouse was studied under and after chronic imipramine treatment in two groups of cats - non-killers and killers. Imiprarnine facilitated predatory behavior in the non-killers but not in the killers, which is in contrast to results obtained on rats. Imipramine produced a marked decrease of locomotor activity of non-killers tested in open field. The inhibition of locomotion did not interfere with the occurrence of killing behavior. It was concluded that imipramine selectively facilitates the neurophysiological mechanism of predatory behavior, which in cats might be connected with the reward system.

Animals↗
PubMed1987

Implications of restrictive diagnosis for compliance to antidepressant drug therapy: alprazolam versus imipramine.

Early dropouts from a double-blind comparison of the therapeutic efficacy of alprazolam and imipramine were examined. The dropout rate across the total sample of 99 analyzable outpatients with major depression was 3 times higher in the imipramine treatment group. Although essentially all patients met DSM-III criteria for major depressive episode, only two thirds of the total sample met the restrictive Feighner criteria for primary depressive disorder. Early termination in the imipramine group was concentrated in the group of depressed outpatients who failed to satisfy the Feighner criteria. Implications of these and other recently reported results for choice of drug treatment for depressed psychiatric outpatients are discussed.

Alprazolam↗
PubMed1987

An outpatient evaluation of phenelzine and imipramine.

Phenelzine and imipramine were evaluated in a 5-week double-blind study of outpatients with major depression. Median daily doses of phenelzine 75 mg and imipramine 150 mg were employed. Of 27 patients 26 completed the 5-week study. Both drugs produced an equal overall effect, as measured by the Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI). When patients were grouped on the basis of panic attack symptoms, phenelzine was found to be more effective than imipramine (p less than .05 for all patients on the BDI; p less than .05 for women on both rating scales).

Adult↗
PubMed1987

Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam.

Night-terrors and somnambulism are comparatively rare in adults and are most often associated with stage 4 sleep, especially delta activity. Although the data are limited, reports suggest that imipramine, which may control nocturnal enuresis, a stage 4 sleep disorder, and diazepam, which suppresses stage 4 sleep, may effectively treat the condition. This paper describes two patients with night-terrors and somnambulism who responded to imipramine but not to diazepam. Possible mechanisms of diazepam and imipramine, including effects on stage 4 sleep and pervasive anxiolytic actions, are discussed.

Adult↗
PubMedDate not supplied

Circadian rhythm of circulating corticosterone and urinary excretion of catecholamines, serotonin and their catabolites in rats treated with imipramine.

The circadian rhythm of serum corticosterone was assessed in rats entrained to a 12:12 LD cycle and treated with tricyclic imipramine (25 mg/kg/day) via osmotic pumps for a period of 14 days; urinary excretion of catecholamines, serotonin and their catabolites was also assessed. We observed that imipramine did not modify the phase position of the corticosterone rhythm but rather lowered the animal's responsiveness as shown by the lower peak of corticosterone at 2000 and by the smaller amplitude of its circadian rhythm; moreover imipramine had no effect on urinary excretion of catecholamines, serotonin and their catabolites during LD cycle.

Animals↗
PubMed1985

Predatory dominance and aggressive display under imipramine treatment in cats.

The effect of imipramine treatment on the aggressive display and predatory dominance was tested in 16 male cats yoked in 8 pairs. Imipramine applied chronically during 3 weeks in submissive cats produced a tendency to compete with the dominant cat in a predatory situation and an accompanying enhancement of aggressive display. Some of the treated cats gained the predatory dominance over previously dominant partners. The level of aggressiveness was not, however, directly related with the process of gaining dominance. Therefore it was concluded that imipramine enhances some mechanisms involved in dominance, not limited to aggression.

Aggression↗